Sanofi, a provider of diabetes devices, has opened a Lantus SoloSTAR Pen assembly plant in Beijing, china.
The Lantus SoloSTAR plant with a capacity of 48 million units per year is designed to produce Lantus SoloSTAR pre-filled insulin injection pens.
Sanofi chief executive officer Christopher Viehbacher said in the second phase of the $90m project, the company is planning to install a cartridge aseptic production line.
"The local production of Lantus SoloSTAR marks an important milestone for Sanofi’s commitment to China and our global commitment to fighting diabetes," Viehbacher added.
"In the coming years, Sanofi will bring integrated and personalized solutions to Chinese patients, including oral anti-diabetic drugs, insulins, glucose monitoring devices, and enhanced services to help patients achieve better outcomes."
Sanofi’s diabetes portfolio also includes blood glucose meters including BGStar and iBGStar.